Michael Patrick Dillon,Mika Lindvall,Daniel Poon,Savithri Ramurthy,Vivek Rauniyar,Cynthia Shafer,Sharadha Subramanian,Huw Rowland Tanner
申请号：
US14428546
公开号：
US09546173B2
申请日:
2013.09.17
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof； as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics.
